Brought to you by
Join us, as we bring together experts in the field to explore the latest advancements and their transformative potential in disease detection. The session will delve into key breakthroughs that have enhanced the sensitivity and specificity of liquid biopsy techniques, making them a powerful tool for early diagnosis and monitoring of various diseases.
Date: 2nd October 2024
Start time: 11:20 (UK time)
End time: 12:20 (UK time)
Venue: ExCeL London,
Address: Royal Victoria Dock, 1 Western Gateway, London E16 1XL
Conference Theatre: Learning Zone
Technological Innovations:
Examination of cutting-edge technologies that have improved the detection of biomarkers in samples.
Clinical Applications:
Discussion on how liquid biopsy is being integrated into clinical practice for early cancer detection, treatment monitoring, and prognosis assessment.
Challenges and Solutions:
Addressing the current limitations of liquid biopsy, along with potential solutions.
Future Directions:
Insights into ongoing research and prospects for liquid biopsy, including its role in personalized medicine and its integration with other diagnostic modalities like artificial intelligence.
Speaker details go here
Speaker details go here
Speaker details go here
Speaker details go here
Since 2014, Dr James Hassall has been primarily developing molecular diagnostic assays to improve patient outcomes, initially through academia and later through industry. James holds an MSc in Oncology and PhD in Pathology from the University of Nottingham and is specialised in Polymerase Chain Reaction (PCR) research & development to ISO13485 and CE-IVD level.
Since 2014, Dr James Hassall has been primarily developing molecular diagnostic assays to improve patient outcomes, initially through academia and later through industry. James holds an MSc in Oncology and PhD in Pathology from the University of Nottingham and is specialised in Polymerase Chain Reaction (PCR) research & development to ISO13485 and CE-IVD level. He has mainly focused on diagnostics in the Oncology setting which he is very passionate about, particularly liquid biopsy and FFPE tumour tissue analysis. James has focused on improving qPCR sensitivity, specifically multiplexed mutation detection so that it is comparable to digital PCR and NGS with the rationale that test accessibility is key to global adoption. James also works on pushing boundaries with rapid extraction-free or inhibitor tolerant multiplexed PCR or mutation detection PCR across all fields such as human disease, veterinary, virology, bacteriology, agriculture and forensics.
James founded his own company, SHARD DIAGNOSTICS Ltd in 2024 as he is keen to break down barriers to entry for molecular diagnostics by providing expansive support and training for all levels of entry alongside collaborative custom research and diagnostic PCR kits (single kit or batch). James is keen to work with academics and industry partners to further enable their day-to-day research capabilities and ultimate visions in the clinical space.
Dr Elad Katz has been developing organoid-based drug discovery in the University of Dundee. This activity has been based on his inventive technology, NaviPlate and is the basis for three commercial projects. Having trained initially in chemistry, Elad did his PhD in immunology in University of Glasgow. During his post-doc in the USA, he became interested in complex biology, through 3D cell cultures of cancer cells. Dr Katz has been passionate about bringing these systems into mainstream drug discovery to the benefit of patients with unmet clinical needs. He has been involved in two successful spin-outs in this space and is hoping to manage a third next year.
Dr. Maria Neofytou, a highly qualified researcher in the field of liquid biopsies, has recently secured an independent faculty position at the University of Westminster in London. With an MSc in Prenatal Genetics and Fetal Medicine from University College London (UCL) and a PhD from the Cyprus Institute of Neurology and Genetics under the guidance of Prof Philippos Patsalis, Dr. Neofytou brings with her a wealth of experience.
Dr. Maria Neofytou, a highly qualified researcher in the field of liquid biopsies, has recently secured an independent faculty position at the University of Westminster in London. With an MSc in Prenatal Genetics and Fetal Medicine from University College London (UCL) and a PhD from the Cyprus Institute of Neurology and Genetics under the guidance of Prof Philippos Patsalis, Dr. Neofytou brings with her a wealth of experience. She spent four years working at the distinguished Cancer Research UK Institute in Cambridge, in the group of Prof Nitzan Rosenfeld a pioneer in the field of liquid biopsies. She has also worked at Oxford University in the UK and the Department of Genetics & Genomics at KU Leuven in Belgium as a postdoctoral researcher. Dr. Neofytou has an extensive research background resulting in multiple publications in peer-reviewed scientific journals, and she has presented her findings at several European and international conferences. Her research interest primarily focuses on biomarker discovery for cancer detection and prenatal diagnosis using circulating nucleic acids, making her a valuable addition to the academic community in London.
James Schofield is an expert in Systems Biomedicine. He is the CEO of TopMD Precision Medicine Ltd, which specialises in pathway biomarkers of functional genomic data from liquid biopsies. He was previously lecturing and researching at the University of Southampton, applying and developing technologies to define molecular phenotypes and their underlying biological mechanisms from multi-‘omics data.
Dr Atreyee Saha, Director of Laboratory and Technologies, Datar Cancer Genetics UK.
Dr Atreyee Saha, Director of Laboratory and Technologies, Datar Cancer Genetics UK.
Seasoned leader with more than a decade-long track record of driving innovation and success in the molecular diagnostics and in vitro medical device (IVD) industry across continents. Proven expertise in leading cross-functional teams, securing funding, fostering strategic partnerships, and navigating complex regulatory environments. Demonstrated success in developing, commercialising, and launching cutting-edge IVD medical devices, delivering exceptional results throughout my career. Committed to scientific excellence and driving positive impact through innovative diagnostic solutions.
Jinyu Shan is a skilled and accomplished microbiologist with experience in academia and industry, specialising in medical microbiology, molecular marker discovery, phage therapy, and infectious disease diagnostics, including Lyme and tick-borne diseases.
Jinyu Shan is a skilled and accomplished microbiologist with experience in academia and industry, specialising in medical microbiology, molecular marker discovery, phage therapy, and infectious disease diagnostics, including Lyme and tick-borne diseases.
After his PhD, Jinyu joined the University of Leicester, focusing on exploring the frontiers of phage-based diagnostics and therapeutics for bacterial infections and antimicrobial resistance. He pioneered phage-based biomarker research for Lyme and tick-borne disease diagnosis, resulting in 20 publications and a licensed patent, benefiting the Lyme community.
In industry, he has led operations and R&D under ISO standards, developing diagnostic tests. Jinyu has judged the LymeX Diagnostics Prize and guest-edited several journals on phage therapy and tick-borne diseases.
Brought to you by Drug Target Review and supported by BioIVT
Drug Target Review is the essential resource for researchers and scientific leaders in drug discovery and early-phase therapeutic development. We provide a voice for the drug discovery industry, promoting the most recent research, developments and cutting-edge technological progression, ensuring that the pharmaceutical and life science community are kept up-to-date with the latest advancements.
